Alamast

Alamast is a brand name of pemirolast ophthalmic, approved by the FDA in the following formulation(s):

ALAMAST (pemirolast potassium - solution/drops; ophthalmic)

• 
  Manufacturer: SANTEN
  
  Approval date: September 24, 1999
  
  Strength(s): 0.1% ^[RLD]

Has a generic version of Alamast been approved?

No. There is currently no therapeutically equivalent version of Alamast available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Alamast. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Anti-allergic ophthalmics
  Patent 5,034,230
  Issued: July 23, 1991
  Inventor(s): Morita; Takakazu & Iso; Tadashi & Kawashima; Youichi & Hikida; Mitsushi
  Assignee(s): Santen Pharmaceutical Co., Ltd.
  This invention relates to low irritative ophthalmics containing the compound of the formula or salts thereof which are useful for treatment of anti-allergic eye diseases such as allergic conjunctivitis ##STR1##
  
  Patent expiration dates:
  
  
  • July 2, 2011
    
    ✓ 
    Patent use: TREATING ALLERGIC EYE DISEASES IN HUMANS
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Alamast Consumer Information (Wolters Kluwer)
• Alamast Consumer Information (Cerner Multum)
• Alamast Advanced Consumer Information (Micromedex)
• Alamast AHFS DI Monographs (ASHP)
• Pemirolast Consumer Information (Wolters Kluwer)
• Pemirolast ophthalmic Consumer Information (Cerner Multum)
• Pemirolast Ophthalmic Advanced Consumer Information (Micromedex)
• Pemirolast Potassium AHFS DI Monographs (ASHP)